Analyst Ratings for G1 Therapeutics
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 7 analysts have published their opinion on G1 Therapeutics (NASDAQ:GTHX) stock. The company has an average price target of $12.71, representing a 29.39% decrease from the previous average price target of $18.00.
August 04, 2023 | 2:12 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have lowered their price target for G1 Therapeutics (NASDAQ:GTHX) over the past 3 months.
The decrease in the average price target for G1 Therapeutics suggests that analysts have a less optimistic outlook for the stock, which could negatively impact its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100